| BIOGEN INC. DL -,0005 | 223.8000 / -1.43% |
News
- Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program
02/24/2021 / 13:30 - GlobeNewswire - Biogen Announces the Expiration Date Results of Its Cash Tender Offer
02/11/2021 / 14:03 - GlobeNewswire - Biogen Announces the Expiration Date Results of Its Private Exchange Offer
02/11/2021 / 14:00 - GlobeNewswire - Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups
02/11/2021 / 13:30 - GlobeNewswire - Biogen Announces the Pricing Terms of its Cash Tender Offer
02/10/2021 / 19:02 - GlobeNewswire - Biogen Announces the Pricing Terms of Its Private Exchange Offer
02/10/2021 / 19:00 - GlobeNewswire - Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only
02/04/2021 / 15:02 - GlobeNewswire - Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors
02/04/2021 / 15:00 - GlobeNewswire - Biogen says Q4 revenue fell 22% to $2.85B
02/03/2021 / 13:07 - TeleTrader - Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
02/01/2021 / 13:30 - GlobeNewswire - Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
01/29/2021 / 13:30 - GlobeNewswire - Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
01/11/2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
01/08/2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
12/21/2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
12/17/2020 / 20:04 - TeleTrader
Real-time